Conference Coverage (Palm Springs)

Protective Mucosal Immunity From PCLUS HIV Vaccine

Published in Vaccine Weekly, April 27th, 1998

An improved peptide-cluster HIV vaccine protected against rectal challenge in a mouse model of HIV infection.

The protection was the first demonstration that local administration of an artificial peptide-based vaccine elicited long-lasting, HIV specific local mucosal and systemic cytotoxic T-lymphocyte (CTL) responses.

"We can't be sure that the protection was due to lytic activity," said Jay Berzofsky of the National Cancer Institute, Bethesda, Maryland. "But there is clear evidence that one can get protection against mucosal challenge by stimulating CD8⁺ cells locally."

Berzofsky spoke in a presentation to the 1998...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-04-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry